Resource Summary Report

Generated by kravitz2 on Aug 9, 2026

pcDNA3.3_CoV2_501V2

RRID:Addgene_170449
Type: Plasmid

Proper Citation

RRID:Addgene_170449

Plasmid Information

URL: http://www.addgene.org/170449

Proper Citation: RRID:Addgene_170449

Insert Name: SARS-CoV-2 501V2 spike D18

Organism: SARS-CoV-2, 501V2 (B.1.351)

Bacterial Resistance: Ampicillin

Defining Citation: PMID:34016740

Vector Backbone Description: Backbone Size:5500; Vector Backbone:pcDNA3.3; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: Please visit https://www.biorxiv.org/content/10.1101/2021.02.16.430500v1 for bioRxiv preprint.

Plasmid Name: pcDNA3.3_CoV2_501V2

Relevant Mutation: L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V; 18aa deletion in c-terminal tail

Record Creation Time: 20220422T221952+0000

Record Last Update: 20260808T081218+0000

Ratings and Alerts

No rating or validation information has been found for pcDNA3.3_CoV2_501V2.

No alerts have been found for pcDNA3.3_CoV2_501V2.

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at kravitz2 .

Zúñiga R, et al. (2025) Bromhexine inhibits SARS-CoV-2 Omicron and variant pseudovirus infection via ACE2-targeted mechanisms. Frontiers in pharmacology, 16, 1745277.

Milewska A, et al. (2025) Evolution of the SARS-CoV-2 spike protein in utilizing host transmembrane serine proteases. iScience, 28(9), 113318.

Shukla N, et al. (2024) Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. bioRxiv : the preprint server for biology.

Thümmler L, et al. (2024) Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants. Viruses, 16(4).

Eden T, et al. (2024) Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications, 15(1), 4728.

Shukla N, et al. (2024) Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. PLoS pathogens, 20(5), e1012044.

Dacon C, et al. (2023) Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Cell host & microbe, 31(1), 97.

Ahmed N, et al. (2023) microRNA-185 Inhibits SARS-CoV-2 Infection through the Modulation of the Host's Lipid Microenvironment. Viruses, 15(9).

Song J, et al. (2022) LRRC15 inhibits SARS-CoV-2 cellular entry in trans. PLoS biology, 20(10), e3001805.

Kuzikov M, et al. (2022) High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 151, 113104.

Shah M, et al. (2022) SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Computational and structural biotechnology journal, 20, 2042.

Chiu CH, et al. (2022) Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities. Frontiers in cellular and infection microbiology, 12, 862656.

Song J, et al. (2021) LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans. bioRxiv : the preprint server for biology.